Alleviative Effects of Low-Dose Lactulose Combined with Bacillus pumilus NJAUYBN1-7 on Slow Transit Constipation in Loperamide-Induced Mice

Clicks: 19
ID: 330712
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #118 of 208 articles by views in Journal of applied microbiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIMS: Slow transit constipation (STC) is a common functional gastrointestinal disorder characterized by intestinal motility dysfunction, barrier damage, hormonal imbalance and gut microbiota dysbiosis. High-concentration (50%) lactulose is routinely used for STC treatment, while Bacillus pumilus acts as a probiotic to regulate intestinal flora. However, the synergistic efficacy and mechanism of low-dose lactulose combined with Bacillus pumilus NJAUYBN1-7 for STC remain unclear. This study aimed to clarify the therapeutic effects and underlying mechanisms of this combined therapy and compare its efficacy with conventional high-dose lactulose monotherapy. METHODS AND RESULTS: A loperamide-induced mouse STC model was applied for efficacy evaluation. Compared with 50% lactulose monotherapy, 30% lactulose combined with vegetative cells of Bacillus pumilus NJAUYBN1-7 (2.0 × 109 CFU·mL-1) significantly relieved constipation symptoms and shortened the first defecation time to 174.5 ± 9.14 min. Meanwhile, fecal output, fecal water content (52.08 ± 5.33%) and intestinal transit rate (49.38 ± 2.46%) were markedly increased. Mechanistically, the combination restored the SCF/Kit pathway, significantly upregulated the expression of intestinal barrier-related proteins (P < 0.05), normalized gastrointestinal hormone concentrations, alleviated colonic inflammation by reducing pro-inflammatory cytokine levels (P < 0.05), and remodeled gut microbiota homeostasis by altering the relative abundance of key enteric bacteria. CONCLUSIONS: 30% lactulose combined with Bacillus pumilus NJAUYBN1-7 exhibits superior STC therapeutic effects compared with 50% lactulose monotherapy. This synergistic regimen improves intestinal motility, repairs intestinal barrier, relieves inflammation and optimizes intestinal microenvironment via multi-target regulation. This study provides novel mechanistic insights and validates the clinical translational potential of this safe and efficient combined strategy for STC treatment.
Reference Key
openalex_W7214983185 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Youdan Sun, Xiaoyan Zheng, GuiYing Dai, Changsheng Chen, Sichao Mao, Xinyi Xu, Xingxiang Chen
Journal Journal of applied microbiology
Year 2026
DOI
10.1093/jambio/lxag244
URL
https://doi.org/10.1093/jambio/lxag244
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.